Design and synthesis of novel deoxybenzoin derivatives as FabH inhibitors and anti-inflammatory agents

β-Ketoacyl-acyl carrier protein synthase III (FabH) catalyzes the initial step of fatty acid biosynthesis via a type II fatty acid synthase in most bacteria. The important role of this essential enzyme combined with its unique structural features and ubiquitous occurrence in bacteria has made it an attractive new target for the development of new FabH inhibitors. The synthesis and biological evaluation halide-deoxybenzoins derivatives are described in this Letter. Potent FabH inhibitory and selective anti-Gram-negative bacteria activities were observed in deoxybenzoin derivatives. Furthermore, compound 19 was able to reduce the ECE-induced IL-8 production in gastric mucosal cells significantly. Based on the biological data and molecular docking, compound 19 is a potential FabH inhibitor and anti-inflammatory agent deserving further research.

A novel series of deoxybenzoin derivatives were designed and synthesized. Based on the biological data obtained in this study, it can be concluded that compound 19 would be a potential Escherichia coli FabH inhibitor and promising anti-inflammatory agent. The binding model of compound 19 and E. coli FabH was also been researched.Figure optionsDownload as PowerPoint slide